PURPOSE: To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB). PATIENTS AND METHODS: Enrolled patients received two cycles of topotecan (approximately 1.2 mg/m(2)/d) and cyclophosphamide (400 mg/m(2)/d) for 5 days followed by four cycles of multiagent chemotherapy (Memorial Sloan-Kettering Cancer Center [MSKCC] regimen). Pharmacokinetically guided topotecan dosing (target systemic exposure with area under the curve of 50 to 70 ng/mL/hr) was performed. Peripheral-blood stem cell (PBSC) harvest and surgical resection of residual primary tumor occurred after cycles 2 and 5, respectively. Patients achieving at least a partial response received myeloablative chemotherapy with PBSC rescue and radiation to the presurgical primary tumor volume. Oral 13-cis-retinoic acid maintenance therapy was administered twice daily for 14 days in six 28-day cycles. RESULTS: Thirty-one patients were enrolled onto the study. No deaths related to toxicity or dose-limiting toxicities occurred during induction. Mucositis rarely occurred after topotecan cycles (9.7%) in contrast to 30% after MSKCC cycles. Thirty patients underwent PBSC collection with median 31.1 × 10(6) CD34+ cells/kg (range, 1.8 to 541.8 × 10(6) CD34+ cells/kg), all negative for tumor contamination by immunocytochemical analysis. Targeted topotecan systemic exposure was achieved in 26 (84%) of 31 patients. At the end of induction, 26 patients (84%) had tumor response and one patient had progressive disease. In the overall cohort, 3-year event-free and overall survival were 37.8% ± 9.4% and 57.1% ± 9.4%, respectively. CONCLUSION: This pilot induction regimen was well tolerated with expected and reversible toxicities. These data support investigation of efficacy in a phase III clinical trial for newly diagnosed HRNB.
PURPOSE: To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB). PATIENTS AND METHODS: Enrolled patients received two cycles of topotecan (approximately 1.2 mg/m(2)/d) and cyclophosphamide (400 mg/m(2)/d) for 5 days followed by four cycles of multiagent chemotherapy (Memorial Sloan-Kettering Cancer Center [MSKCC] regimen). Pharmacokinetically guided topotecan dosing (target systemic exposure with area under the curve of 50 to 70 ng/mL/hr) was performed. Peripheral-blood stem cell (PBSC) harvest and surgical resection of residual primary tumor occurred after cycles 2 and 5, respectively. Patients achieving at least a partial response received myeloablative chemotherapy with PBSC rescue and radiation to the presurgical primary tumor volume. Oral 13-cis-retinoic acid maintenance therapy was administered twice daily for 14 days in six 28-day cycles. RESULTS: Thirty-one patients were enrolled onto the study. No deaths related to toxicity or dose-limiting toxicities occurred during induction. Mucositis rarely occurred after topotecan cycles (9.7%) in contrast to 30% after MSKCC cycles. Thirty patients underwent PBSC collection with median 31.1 × 10(6) CD34+ cells/kg (range, 1.8 to 541.8 × 10(6) CD34+ cells/kg), all negative for tumor contamination by immunocytochemical analysis. Targeted topotecan systemic exposure was achieved in 26 (84%) of 31 patients. At the end of induction, 26 patients (84%) had tumor response and one patient had progressive disease. In the overall cohort, 3-year event-free and overall survival were 37.8% ± 9.4% and 57.1% ± 9.4%, respectively. CONCLUSION: This pilot induction regimen was well tolerated with expected and reversible toxicities. These data support investigation of efficacy in a phase III clinical trial for newly diagnosed HRNB.
Authors: D G Tubergen; C F Stewart; C B Pratt; W C Zamboni; N Winick; V M Santana; Z A Dryer; J Kurtzberg; B Bell; H Grier; T J Vietti Journal: J Pediatr Hematol Oncol Date: 1996-11 Impact factor: 1.289
Authors: W C Zamboni; L C Bowman; M Tan; V M Santana; P J Houghton; W H Meyer; C B Pratt; R L Heideman; A J Gajjar; A S Pappo; C F Stewart Journal: Cancer Chemother Pharmacol Date: 1999 Impact factor: 3.333
Authors: R Ladenstein; T Philip; C Lasset; O Hartmann; A Garaventa; R Pinkerton; J Michon; J Pritchard; T Klingebiel; B Kremens; A Pearson; C Coze; P Paolucci; D Frappaz; H Gadner; F Chauvin Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: W C Zamboni; C F Stewart; J Thompson; V M Santana; P J Cheshire; L B Richmond; X Luo; C Poquette; J A Houghton; P J Houghton Journal: J Natl Cancer Inst Date: 1998-04-01 Impact factor: 13.506
Authors: Wendy B London; Christopher N Frantz; Laura A Campbell; Robert C Seeger; Babette A Brumback; Susan L Cohn; Katherine K Matthay; Robert P Castleberry; Lisa Diller Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544
Authors: S O'Reilly; E K Rowinsky; W Slichenmyer; R C Donehower; A A Forastiere; D S Ettinger; T L Chen; S Sartorius; L B Grochow Journal: J Clin Oncol Date: 1996-12 Impact factor: 44.544
Authors: R Nitschke; J Parkhurst; J Sullivan; M B Harris; M Bernstein; C Pratt Journal: J Pediatr Hematol Oncol Date: 1998 Jul-Aug Impact factor: 1.289
Authors: S H Kaufmann; D Peereboom; C A Buckwalter; P A Svingen; L B Grochow; R C Donehower; E K Rowinsky Journal: J Natl Cancer Inst Date: 1996-06-05 Impact factor: 13.506
Authors: B H Kushner; M P LaQuaglia; M A Bonilla; K Lindsley; N Rosenfield; S Yeh; J Eddy; W L Gerald; G Heller; N K Cheung Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544
Authors: Steve E Braunstein; Wendy B London; Susan G Kreissman; Judith G Villablanca; Andrew M Davidoff; Kenneth DeSantes; Robert P Castleberry; Kevin Murray; Lisa Diller; Katherine Matthay; Susan L Cohn; Barry Shulkin; Daniel von Allmen; Marguerite T Parisi; Collin Van Ryn; Julie R Park; Michael P La Quaglia; Daphne A Haas-Kogan Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2020-07-25 Impact factor: 3.167
Authors: Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman Journal: Biol Blood Marrow Transplant Date: 2017-07-18 Impact factor: 5.742
Authors: Navin Pinto; Arlene Naranjo; Emily Hibbitts; Susan G Kreissman; M Meaghan Granger; Meredith S Irwin; Rochelle Bagatell; Wendy B London; Emily G Greengard; Julie R Park; Steven G DuBois Journal: Eur J Cancer Date: 2019-04-01 Impact factor: 9.162
Authors: Richard Aplenc; Rochelle Bagatell; Ami V Desai; Marko Kavcic; Yuan-Shung Huang; Nicole Herbst; Brian T Fisher; Alix E Seif; Yimei Li; Sean Hennessy Journal: Pediatr Blood Cancer Date: 2014-01-13 Impact factor: 3.167
Authors: Brian H Kushner; Irina Ostrovnaya; Irene Y Cheung; Deborah Kuk; Kim Kramer; Shakeel Modak; Karima Yataghene; N K Cheung Journal: Oncoimmunology Date: 2015-05-22 Impact factor: 8.110